Fourier, Anthony
Escal, Jean
Bernard, Emilien
Lachman, Ingolf
Perret-Liaudet, Armand
Leblanc, Pascal
Quadrio, Isabelle
Article History
Received: 13 August 2018
Revised: 11 October 2018
Accepted: 18 October 2018
First Online: 29 October 2018
Compliance with ethical standards
:
: Ingolf Lachmann provided 2G10 antibody and reports that he is employee of AJ Roboscreen GmbH®, Leipzig, Germany. No other conflict of interest is reported.
: This study was based on biological samples collected for routine diagnosis in the framework of a medical follow-up recommended for FTLD patients. The samples associated to written consents were stored in a bio bank with the authorization from the French Ministry of Health (Declaration Number DC-2008-304). Authorization for handling personal data was granted by the French data protection commission [Commission Nationale de l’Informatique et des Libertés (CNIL)].The patients included in this study or their legal next of kin gave two informed written consents: the first one for FTLD genetic testing and the second one authorizing a change of biological purpose for remaining parts of samples.